Abstract
Antipsychotic medications are important for the successful management of schizophrenia. Continuous treatment with medication is superior in relapse prevention and non-adherence to antipsychotic medication is associated with a poor clinical outcome. Long-acting injectable antipsychotics (LAIs) that can guarantee adherence to a treatment regimen could be a useful treatment option. With the introduction of second-generation atypical antipsychotics-long acting injection (SGA-LAI), the risks for extrapyramidal adverse events are decreased. The indications for SGA-LAI have been extended from chronic, stabilized patients to acute psychotic patients. Some studies investigated the use of LAI in first-episode schizophrenia patients and raised the possibility of prescribing LAI as a treatment option. However, there is still limited research using LAI in first-episode schizophrenia. More well-designed, randomized, controlled clinical trials using SGA-LAIs in first episode schizophrenia are needed. Additionally, studies on side effects of SGA-LAI in long-term use are required prior to recommending LAI for patients with first episode schizophrenia.
| Original language | English |
|---|---|
| Pages (from-to) | 1-6 |
| Number of pages | 6 |
| Journal | Clinical Psychopharmacology and Neuroscience |
| Volume | 11 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2013 Apr 1 |
Fingerprint
Keywords
- Antipsychotic agents
- Delayed-action preparations
- Injections
- Schizophrenia
ASJC Scopus subject areas
- Behavioral Neuroscience
- Pharmacology (medical)
- Psychiatry and Mental health
Cite this
Long-acting injectable antipsychotics in first-episode schizophrenia. / Jeong, Hyun-Ghang; Lee, Moon-Soo.
In: Clinical Psychopharmacology and Neuroscience, Vol. 11, No. 1, 01.04.2013, p. 1-6.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Long-acting injectable antipsychotics in first-episode schizophrenia
AU - Jeong, Hyun-Ghang
AU - Lee, Moon-Soo
PY - 2013/4/1
Y1 - 2013/4/1
N2 - Antipsychotic medications are important for the successful management of schizophrenia. Continuous treatment with medication is superior in relapse prevention and non-adherence to antipsychotic medication is associated with a poor clinical outcome. Long-acting injectable antipsychotics (LAIs) that can guarantee adherence to a treatment regimen could be a useful treatment option. With the introduction of second-generation atypical antipsychotics-long acting injection (SGA-LAI), the risks for extrapyramidal adverse events are decreased. The indications for SGA-LAI have been extended from chronic, stabilized patients to acute psychotic patients. Some studies investigated the use of LAI in first-episode schizophrenia patients and raised the possibility of prescribing LAI as a treatment option. However, there is still limited research using LAI in first-episode schizophrenia. More well-designed, randomized, controlled clinical trials using SGA-LAIs in first episode schizophrenia are needed. Additionally, studies on side effects of SGA-LAI in long-term use are required prior to recommending LAI for patients with first episode schizophrenia.
AB - Antipsychotic medications are important for the successful management of schizophrenia. Continuous treatment with medication is superior in relapse prevention and non-adherence to antipsychotic medication is associated with a poor clinical outcome. Long-acting injectable antipsychotics (LAIs) that can guarantee adherence to a treatment regimen could be a useful treatment option. With the introduction of second-generation atypical antipsychotics-long acting injection (SGA-LAI), the risks for extrapyramidal adverse events are decreased. The indications for SGA-LAI have been extended from chronic, stabilized patients to acute psychotic patients. Some studies investigated the use of LAI in first-episode schizophrenia patients and raised the possibility of prescribing LAI as a treatment option. However, there is still limited research using LAI in first-episode schizophrenia. More well-designed, randomized, controlled clinical trials using SGA-LAIs in first episode schizophrenia are needed. Additionally, studies on side effects of SGA-LAI in long-term use are required prior to recommending LAI for patients with first episode schizophrenia.
KW - Antipsychotic agents
KW - Delayed-action preparations
KW - Injections
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=84876947774&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876947774&partnerID=8YFLogxK
U2 - 10.9758/cpn.2013.11.1.1
DO - 10.9758/cpn.2013.11.1.1
M3 - Article
C2 - 23678347
AN - SCOPUS:84876947774
VL - 11
SP - 1
EP - 6
JO - Clinical Psychopharmacology and Neuroscience
JF - Clinical Psychopharmacology and Neuroscience
SN - 1738-1088
IS - 1
ER -